Archived OBR Journal Articles

May 2012 - Table of Contents

The Rise of Companion Diagnostics: A Step Towards Truly Personalized Medicine [read article]
Kantar Health’s Top Picks: What’s Hot at ASCO 2012 [read article]
Peter B. Bach, MD, and the Case for Interchangeability in Oncology: A New Model for an Episode-based Payment System [read article]
Achieving Accountable Cancer Care [read article]
On-Conversation with Michael N. Neuss, MD, Chief Medical Officer of the Vanderbilt-Ingram Cancer Center [read article]
Diagnostic Testing and Clinical Pathways Move into the PA Neighborhood [read article]
Spotlight on Cost of Cancer Care: Panitumumab [read article]

March 2012 - Table of Contents

Solid Tumor Agents Dominate the Future of Biomarkers [read article]
After an Eventful 2011, What’s in the Pipeline for Emerging Technologies in Oncology? [read article]
Spotlight on Cost of Cancer Care: Rituximab [read article]
The Use of Hsp90 Inhibitors in the Treatment of Lung Cancer [read article]
Digital Patient Engagement: Next Steps in the Provider-Patient Relationship [read article]

January 2012 - Table of Contents

New Frontiers and Novel Mechanism of Action in Hematologic Malignancies [read article]
Shining a Light: How the Sunshine Provision May Impact Promotion [read article]
Consumerism in Oncology: How Will it Affect Cancer Care? [read article]
The OBR Top 10 Oncology Stories of 2011 [read article]
The 4th Annual Outlook on the Pharmaceutical Promotional Landscape Within Oncology [read article]

November 2011 - Table of Contents

On-Conversation with Jeff Patton, MD, Chief Executive Officer Tennessee Oncology, Chief Medical Officer RainTree Oncology Services [read article]
Regional Variances in European Pancreatic Cancer Treatment and the Influential Power of Clinical Trial Participation [read article]
Consolidations Come with Concerns as NCI Cooperative Groups Restructure [read article]
Baker's Dozen Attempting to Beat the Odds in Pancreatic Cancer [read article]
Relating Value in Cancer Care to Cost and Outcome [read article]
Oncologists' Perspectives on the Future of Biosimilars [read article]
Spotlight on Cost of Cancer Care: Bendamustine [read article]

September 2011 - Table of Contents

Embracing Clinical Pathways as a Viable Financial Model [read article]
Spotlight on Cost of Cancer Care: Pemetrexed [read article]
EHRs?Finding the Balance Between Functionality and Mobility [read article]
340B Benefits Some, Not Others: Money Redirected Through Expansion [read article]
Ten Trends Transforming the Business of Oncology [read article]

July 2011 - Table of Contents

Top Media Stories at ASCO 2011 [read article]
Spotlight on Cost of Cancer Care: Cetuximab [read article]
Payers & Providers Agree: Realistic Expectations and Cost-Effective Analyses are Key [read article]
P13K Inhibitors: A promising New Class of Cancer Therapeutics? [read article]
Payer Insights Into the Future of Oncology Management [read article]

May 2011 - Table of Contents

Building the Future of Cancer Care: Taking Multidisciplinary Care to a New Level [read article]
What's in Store at ASCO 2011? Kantar Health Offers a Preview [read article]
Drug Shortages Continue, Solutions are Evolving [read article]
Preference for Oral Cancer Agents on the Rise [read article]
Spotlight on Cost of Cancer Care: Docetaxel [read article]

March 2011 - Table of Contents

Payer Trends: Assisting with End of Life Discussions [read article]
Regulating Molecular and Genetic Tests: NCCN Annual Meeting Coverage [read article]
Epigenetics: Moving Beyond the Early Promise [read article]
From Limbaugh, to ODAC, to FDA and Compendia, the Avastin Debate Continues (at least until June) [read article]
Healthcare Reform: A Bitter Pill for Oncology? [read article]

January 2011 - Table of Contents

2011 Forecast: Experts Provide Perspective on the Coming Year in Oncology [read article]
'10 in Review [read article]
2013: Five Predictions for the Future of Oncology [read article]
Oncology Market Adoption Trends: Quick Poll Results From ASH & SABCS [read article]
The Oncology Professional Services Agreement [read article]
Seeking an Oncology-Specific Accountable Care Model [read article]
The 3rd Annual Outlook on the Pharmaceutical Promotional Landscape Within Oncology [read article]
Spotlight on Cost of Cancer Care [read article]

November 2010 - Table of Contents

Conference Coverage: Highlights from the 2010 Cancer Center Business Summit [read article]
U.K. & U.S. Cost and Comparative Effectiveness Policies Converge [read article]
Past Pitfalls and Potential Promise for Pancreatic Cancer [read article]
Healthcare Reform: Oncology PAP Program Design in the Age of the Federally Insured [read article]
Spotlight on Cost of Cancer Care [read article]
On-Currences [read article]

September 2010 - Table of Contents

The Rise (and Fall?) of Avastin for the Treatment of Advanced Metastatic Breast Cancer [read article]
Implementation of Clinical Pathways: Payers to Share Savings With Pathway Compliant Groups [read article]
The FDA and Laboratory Developed Tests: The Brouhaha Continues [read article]
Cancer Stem-like Cells: The Evolution of a Cancer Theory [read article]
Prior Authorization—Preventing Waste or Waste of Time? [read article]
On-Currences [read article]

July 2010 - Table of Contents

On-Currences [read article]
The EMR Landscape: A Review of the ASCO 2010 EHR Lab [read article]
Taking It Personal–When to Add Biomarkers to Treatment Guidelines [read article]
Factors Driving the Current and Future Use of Oncology Biomarkers [read article]
Innovative Advancements in Treating Cancer: Beyond Targeted Therapies [read article]
ASCO 2010 Top News Stories [read article]
Payer Reactions to Highly Anticipated Clinical Trial Presentations [read article]

May 2010 - Table of Contents

NCCN: Clinical and Economic Issues Impacting Cancer Care Delivery [read article]
Payers Must Create Defensible Oncology Management Strategies [read article]
Expansion of Section 340B Raises New Questions for Cancer Stakeholders [read article]
Models and Mechanisms for Assisting the Underinsured [read article]
Forecasting Success: the Misperceived Influence of FDA Approval [read article]
Onconversation with James Sabry, MD, PhD, Vice President, Genentech Partnering [read article]
On-Currences [read article]
OBR Radar: Keeping an Eye on Market Moving Events [read article]

March 2010 - Table of Contents

The Ongoing Hopes and Challenges of Cancer Vaccines (Part 2 of 2) [read article]
Managing the Health of Your Patients and Your Practice [read article]
Risk-Sharing Schemes in Oncology—Future or Fad? [read article]
A Perspective on Cancer Drug Pricing and Volume [read article]
OBR Radar: Keeping an Eye on Projected Market Moving Events in the Oncology Pipeline [read article]
ON-CURRENCES [read article]

January 2010 - Table of Contents

Collaborative Efforts Speed Outcomes in Cancer Clinical Trials [read article]
2010 Forecast: Experts Provide Perspective on the Coming Year in Oncology [read article]
The Ongoing Hopes and Challenges of Cancer Vaccines (Part 1 of 2) [read article]
A Year-End Look at the Promotional Landscape Within Oncology [read article]
ON-CURRENCES [read article]

November 2009 - Table of Contents

Commercialization of Oncology Medicines and Federal Policy: Why Technology Transfer Offices Should Increase Their Activities on Coverage and Reimbursement Issues [read article]
An Insider’s Guide to Using Oncology-Specific EMRs [read article]
Oncology-Specific EMRs Gain Traction: Suppliers Weigh In [read article]
On-Conversation with Kenneth H. Buetow, PhD [read article]
Attaining Breast Center Accreditation: Merging Market Share Goals with Quality Measures [read article]
Panel Advises on Clinical Pathways: What, Why, and How [read article]
OP-ED: Clinical and Operational Benchmarking With EMRs [read article]
ON-CURRENCES [read article]
IB/MAB WORKSHEET [read article]

September 2009 - Table of Contents

Defining Meaningful Use Criteria for Electronic Health Records: An Early Adopter’s Wish List [read article]
The Increasing Incidence of Special Protocol Assessments [read article]
Compliance Programs Partner in the Management of Oral Cancer Therapies [read article]
Battling the High Cost of Nonadherence with Oral Cancer Therapies [read article]
Oncologists: Cost-Effectiveness Policy Necessary Despite Quality of Care Warnings [read article]
ONCOLOGY BOOK REVIEWS [read article]
ON-CURRENCES [read article]

July 2009 - Table of Contents

The Debate Over Episode-Based Payments in Oncology—Can This System Replace Buy and Bill? [read article]
ACCME Regulation Takes Affect—Changing the CME Industry For Better or For Worse [read article]
Select Biomarkers Possibly Ready for Primetime: EGFR, HER2, and K-ras [read article]
Economy Forcing Oncology Groups to Adjust Business Practices [read article]
ERA-Based Data and Oncology Products: An Opportunity for Practices to Maximize Cash Flow [read article]
ON-CURRENCES [read article]

May 2009 - Table of Contents

Detecting the Future: A Perspective on the Rising Value of Diagnostics in Oncology Therapeutics (Part 2) [read article]
A Bump in the Road: Laboratory Developed Tests Defend Their Regulatory Position [read article]
Competing for Image Leadership [read article]
Adoption of e-Prescribing Yields Surprising Benefits to Practices [read article]
Clinical Trial Landscape in Breast Cancer – Survey From March '09 [read article]
ONCOLOGY BOOK REVIEWS [read article]
ON-CURRENCES [read article]

March 2009 - Table of Contents

OP-ED: Innovative Cancer R&D – Here to Stay [read article]
Tension Rises as Three Products for Hard-to-Treat Tumors Reach a Pivotal Point [read article]
Detecting the Future: A Perspective on the Rising Value of Diagnostics in Oncology Therapeutics (Part 1) [read article]
A P&T Perspective on Adoption of Clinical Guidelines by Payers [read article]
Promising Pipeline Pearls on the Horizon [read article]
Changes in Oncology Practice Business Models Require Changes in Oncology Marketing Strategies: A Case Study Elucidates the Business Model Changes [read article]
Pipeline Perspectives™: Biomerk Tumorgrafts™—An Alternative Approach to Xenografts [read article]
ON-CURRENCES [read article]

January 2009 - Table of Contents

CCBS COVERAGE: Community Oncology at the Crossroads [read article]
The New Administration’s Health Policy and What it Means to You [read article]
’09 Forecast: Oncology Stakeholders Provide Perspective on the Coming Year [read article]
’08 Review: Top 10 Oncology Stories & The Roller Coaster Year for Select Companies [read article]
Targeted Agents Primed to Benefit in Wake of Recent Genomic Data [read article]
Still Using Pen & Paper? [read article]
An Outlook on the Pharmaceutical Promotion Landscape Within Oncology [read article]
ON-CURRENCES [read article]

November 2008 - Table of Contents

Oncology Compendia: Greater Transparency and Regulatory Attention at the Forefront [read article]
Prospecting In Oncology: Analytical Framework Guides Development Strategy Decisions [read article]
Creating Comparative Effectiveness Policy: How Does Oncology Fit? [read article]
Productive Partnering—The Next Stage in Patient Enrollment for Clinical Trials [read article]
Oncology Clinical Trials: The New Battleground? [read article]
Planning to Maximize the Economics of Clinical Trials [read article]
ON-CONVERSATIONS: HillCo Partners Identifies Major Healthcare Policy Trends Which Will Impact Oncology Over the Next 3 to 5 Years [read article]
ON-CURRENCES [read article]

September 2008 - Table of Contents

DDMAC and the Debate Over Off-Label Communications [read article]
The Oncology Pipeline: Maturing, Competitive, and Growing? [read article]
Targeting Therapy: New Approaches to Finding the Next Great Cancer Drug [read article]
Companion Biomarkers and Cancer Treatment: Lessons Learned for Oncology New Product Planning [read article]
Tearing Down Walls: Payers and Providers Align Quality Care and Reimbursement [read article]
Onmark 3rd Annual Office-based Oncology Business Benchmarking Survey: 2008 Report on 2007 Data [read article]

July 2008 - Table of Contents

Perceptions in Oncology Drug Strengths and Weaknesses: Zitter Group Survey Shows Similarities and Disparities Between Payers and Providers [read article]
As the Importance of Biomarkers Increases, Academia and Industry Consider How Best to Respond [read article]
The Physician’s Role in Securing Patient Access to Appropriate Therapies: Sharing the Stage with Patients and Payers [read article]
ASCO '08: Media, Giveaways, and Foot Traffic [read article]
ASCO '08: A Look at the Progress in 3 Different Cancer Types [read article]
ASCO '08: The Competition for Share of Voice Descends Upon Chicago, [read article]
ON-CONOMY: Medicare Policies Change ESA Use and Payment [read article]

May 2008 - Table of Contents

Pioneers in Personalized Medicine—Agendia and Genomic Health Are Changing the Way Patients with Breast Cancer Are Treated [read article]
Cutting Through the Noise: Gaining and Maintaining Share of Voice in Today’s Oncology Marketplace [read article]
Patient Assistance Programs: Good Business & Good Will Go Hand in Hand [read article]
Oncology Drug Denials Slow Payment in Q4 ‘07 [read article]
Emerging mTOR Inhibitors Make Good on Their Initial Promise [read article]
Back to the Future: Original Liquid Leukine® Coming Soon [read article]

March 2008 - Table of Contents

Behind Closed Network Doors: Oral Cancer Drugs and the Rise of Specialty Pharmacy [read article]
Weathering the Storm: How Genentech Looks to Rebuild Confidence and Ride on to Continued Success in 2008 [read article]
Celebrating 25 Years of the Orphan Drug Act [read article]
ESA Policy Raises Hospital Admissions for Transfusions [read article]
Restricted Access: What Happens If the Door Closes to Industry? [read article]
On–Conversation with Daniel Swisher, CEO and President, Sunesis Pharmaceuticals Inc. [read article]

January 2008 - Table of Contents

Compendia: The Bridge Between FDA Approved Indications and Off-label Drug Usage [read article]
The Appeal of Genasense: The Drug, the Data, and the Tangled Web that its FDA Review has Become [read article]
How Does Drug Pricing Drive Therapeutic Choice? A review of a symposium held in conjunction with the American Society of Hematology (ASH) [read article]
’07: In Review. The OBR Top 10 Media Stories & Top 10 Deals of 2007 [read article]
’08: Forecast (Part 1). Oncology Industry Experts Provide Perspective on the Coming Year [read article]
’08: Forecast (Part 2) The View From the Office: How Community Oncologists See 2008 [read article]
Tasigna®: An Innovative TKI from Novartis for Patients with CML [read article]
Biogen Idec: An Oasis for Employees During the Southern California Wildfires [read article]

November 2007 - Table of Contents

Zero Sum Game [read article]
Rituxan® Anniversary: 10 Years of Progress [read article]
The Future of the Present: A Look at the Current and Proposed State Legislature to Regulate and Disclose Gifts [read article]
Evolution of the Oncology GPO [read article]
A New Kind of Cancer Warfare Agent: Next Generation Monoclonal Antibodies [read article]
On-Conversation with Paolo Paoletti, MD, Senior Vice President, Oncology Medicine Development Center, GlaxoSmithKline [read article]
On-Conversation with Craig W. Philips, Vice President & General Manager, Bayer Healthcare [read article]

September 2007 - Table of Contents

Radiopharmaceuticals Need a Jump-STaRT [read article]
The Alphabet Soup of Hematologic Malignancies: Current Therapies Point the Way to Future Breakthroughs [read article]
Ink and Inc.: How ASCO’s Media Policies Affect the Oncology Industry [read article]
Making a Splash at ASCO [read article]
Torisel™: The New Kid on the Block for Advanced Renal Cell Carcinoma [read article]
On-Conversation with Nancy Simonian, M.D. [read article]
On-Conversation with Craig Eagle, Senior Director, Global Oncology, Pfizer Global Pharmaceuticals [read article]
On-Conversation with Bob Oliver, VP & Global Business Manager of the Oncology Franchise at Wyeth Pharmaceuticals [read article]

June 2007 - Table of Contents

The Rising Tide of Generic Cancer Agents [read article]
To Dispense Or Not To Dispense [read article]
Understanding Operational and Financial Benchmarks In The Practice [read article]
GPC Biotech and the Satraplatin Story [read article]
Q&A With David Parkinson, MD, Senior VP of R&D at BiogenIdec [read article]
Oncology Sales Force Effectiveness In An Era of Unprecedented Competition (A Look Ahead) [read article]

May 2007 - Table of Contents

Tykerb: In a Class By Itself [read article]
Therapeutic Cancer Vaccines: The Road to Commercialization [read article]
A Tale of Two Cancer Immunotherapy Companies: Same Tumor Target, Parallel Development, and Very Different Approaches [read article]
Challenges in Reimbursement: Communicating Non-reimbursed Costs to Payers [read article]
Of Mice and MAbs: Medarex [read article]
Improving Compliance in the World of Biotechs: Helping Small Companies Avoid Big Problems [read article]

February 2007 - Table of Contents

Dendreon Steps Up to the Plate, And Cancer Immunotherapy Companies Watch from the Sidelines [read article]
Therapeutic Cancer Vaccines: Elucidating the Differences Between Passive and Active Immunotherapy [read article]
The Science behind Developing Active Immunotherapies: A Look at NHL and Prostate Cancer Therapeutic Vaccines [read article]
Office Practice Managers Speak Their Minds [read article]
OBR Q&A with Michael King, Director of Research at Rodman & Renshaw [read article]
Medicare’s Competitive Acquisition Program: Stats Reveal Who’s In/Who’s Out and Why [read article]

January 2007 - Table of Contents

Spotlight on Exelixis: Big Pipeline—Big Deals—Big Promise? [read article]
Clinical Pathways: Can the Art of Oncology be Managed? [read article]
The Vectibix™ Launch: A Look at the Commercialization of this New Fully-Humanized Antibody for Colorectal Cancer [read article]
Competitive Landscape: Designing the Next Cancer Drugs [read article]
Strategies for Gaining Cancer Drug Approval in '07 [read article]
Molecular Profiling: Using the Genome to Identify Effective Cancer Agents [read article]
Ariad Aligns with Bellicum to Develop Novel Vaccine for Prostate Cancer [read article]

September 2006 - Table of Contents

Spotlight On Celgene: A Cancer Company On The Rise more»
Exhibitor Bang For The Buck? A Look at ASCO Exhinit Hall Floor more»
Oral Cancer Agents Are Changing The Distribution Channel more»
Big Pharma Has A Big ASCO ‘06 more»
Interpretation Of Survival Data From Oncology Clinical Trials more»
mTOR INHIBITORS: Will They Redefine The Blockbuster In Cancer Therapy more»